41 results about "Streptococcus infection" patented technology

The invention relates to a tilapia immune potentiator and a preparation method thereof, and belongs to the technical field of an aquatic compound feed additive. The preparation method is characterized by comprising the following steps: fully mixing curcumin, glutamine, betaine and a carrier; and crushing the components into dry powder. The tilapia immune potentiator has the advantages of stable raw material source, simple preparation process, wide material selection range and low cost; starting from an immune mechanism of fish, Chinese herbal medicines and a western medicine-glutamine dipeptide are supplemented in the immune potentiator; and by means of combination of the traditional Chinese medicines and the western medicine, immunity of the fish is improved. By utilizing the tilapia immune potentiator, the immunity and oxidation resistance of the fish are improved, the capability of tilapia on resisting pathogenic streptococcus infection is strengthened, and growth of the tilapia is promoted.

The (Streptococcus suis Serotype 2 (SS2) virulence gene PCR amplification kit includes a SS2DNA contrast template, a PCR amplification detecting reagent, an agarose gel electrophoresis reagent and a DNA gradient standard. The PCR amplification detecting process includes the measurement of 7 important SS2 genes, diagnosing Streptococcus infection and SS2 infection based on whether to amplify specific Streptococcus gene, specific SS2 gene and 5 relevant important SS2 virulence genes, and predicting the virulence, invasiveness trend and disease prognosis fast and early. The present invention is favorable to the clinical diagnosis of borderline case and early warning, and is hopeful to be applied in emergency detection of human SS2 infection, etc.

The invention discloses a care solution for cleaning a nasal cavity and a preparation method of the care solution. The care solution is prepared from 5,000 parts of traditional Chinese medicine distillate, 0.1-2 parts of preservatives, 1-100 parts of glyceryl polymethacrylate, 20-100 parts of tween 80, 30-80 parts of sodium chloride, 20-60 parts of a pH conditioning agent and 4658-4928.9 parts of purified water. The osmotic pressure of the care solution is 280-310mosm / Kg, and the pH value is 5.5-7.0. The preparation method of the care solution mainly comprises the following steps: by taking one or combination of houttuynia cordata, mint, honeysuckle and radix angelicae as raw materials, carrying out steam distillation to obtain the traditional Chinese medicine distillate; matching with auxiliary materials, and then filtering and carrying out split charging, so as to obtain the care solution. The solution disclosed by the invention has a strong inhibiting effect on nasal common microbe streptococcus infection, staphylococcus, bacillus influenza, influenza viruses and rhinoviruses, and can achieve the target of preventing rhinitis infection and recurrence.

Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

The invention provides application of S. pneumoniae protein to resisting infection of S. pneumoniae. The endopeptidase O (PepO) of S. pneumoniae is a subcutaneous immunologic adjuvant, and the prepared S. pneumoniae protein vaccines have the good protection effects on resisting infection of S. pneumoniae through mixing and fusing expression of the subcutaneous immunologic adjuvant and 673rd to 863rd amino acid peptide fragment of zinc metal protease B (ZmpB).

The invention provides a group B streptococcus nucleic acid assay kit based on a PCR (polymerase chain reaction) fluorescent probe method. The group B streptococcus nucleic acid assay kit comprises nucleic acid releasing agents and PCR reaction fluid, wherein the nucleic acid releasing agents include 0.05-0.5mM / L surfactin, 100-300mM / L potassium chloride, 0.05-3% sodium dodecyl sulfate and 0.01-1% ethyl alcohol, the PCR reaction fluid comprises a forward primer, a reverse primer and a probe, the forward primer and the reverse primer are used for target polynucleotide amplification, and the probe is used for target polynucleotide assay. The group B streptococcus nucleic acid assay kit has the advantages that a nucleic acid release method is adopted, a pathogen coat protein structure is rapidly destroyed by strong protein denaturants, group B streptococcus-DNA (deoxyribonucleic acid) in unknown samples such as genital secretions and rectum secretions of perinatal pregnant women can be assayed rapidly, and assay sensitivity can be up to 500 copies / ml, so that reliable experimental bases are provided for group B streptococcus infection diagnosis, and the problems of poor assay specificity and low sensitivity of the prior art can be solved.

The invention relates to Streptococcus suis infection in pigs, vaccines directed against those infections and tests for diagnosing Streptococcus suis infections. The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of Streptococcus suis or a gene or gene fragment derived thereof. The invention further provides a nucleic acid probe or primer allowing species or serotype-specific detection of Streptococcus suis. The invention also provides a Streptococcus suis antigen and vaccine derived thereof.

The invention relates to bacterial infections, vaccines directed against those infections and bacterial vaccines. More particularly, the invention relates to vaccines directed against Streptococcus infections in pigs. Provided is a [Delta]FolT mutant of a bacterium having reduced capacity to transport folate, wherein the capacity has been reduced by functionally deleting folate transporter (FolT)function. The present invention provides a method to reduce virulence of a bacterium comprising reducing the capacity of the bacterium to transport folate.

The invention discloses a method for detecting group B streptococcus infection, which is characterized in that a detection reagent prepared from hippuric acid or hippurate analogue as a chromogenic substrate and a buffer solution is adopted, and hippuricase in group B streptococcus can be used for specifically recognizing glycine and benzoic acid in the chromogenic substrate and hydrolyzing amido bonds for linking glycine and benzoic acid to change the color of the chromogenic substrate, so that whether group B streptococcus is infected or not in a detected sample is judged. The invention also discloses a kit for detecting group B streptococcus infection. The detection method disclosed by the invention is simple, professional training required for the bacterial streaking technology is not needed, identification results can be obtained only by simple sample adding and short-time incubation, the detection time is far shorter than the time required for culture by a culture medium, and visual identification results are intuitive and accurate. The kit disclosed by the invention is simple in structure, convenient in operation and good in performance. Statistics show that by adopting the kit for detection, the positive predictive value is more than 85%, and the negative predictive value is more than 97%.

The invention discloses a fusion protein vaccine capable of inhibiting Streptococcus and / or preventing Streptococcus infection. With fusion protein obtained through linkage of sortase A and a cholera toxin B subunit through connecting peptide, the Th17 cell activation level is remarkably increased, the effects of preventing pathogenic bacteria from settling and quickly removing the pathogenic bacteria can be realized, and the fusion protein has protecting effects on Group A Streptococcus of different serotypes and has the superiority of high efficiency, broad spectrum and low cost. With the fusion protein, the use amount of immunogen is reduced, the production technology is simplified, and the production cost is reduced. Meanwhile, the vaccine adopts the way of mucosal immunity, has the characteristics of being free of tissue damage, free of local side effects and convenient to use, and is easy to popularize and use.

Polypeptides from Streptococcus pneumoniae are described. In some aspects the polypeptides include pili polypeptides from a second pili island (pilus II island (INVl 04B)) identified in Streptococcus pneumoniae isolate INVl 04. In other aspects the polypeptides include pili polypeptides and non-pilus polypeptides from Streptococcus pneumoniae strains 23F, INV200, and OXC141 that are absent from Streptococcus pneumoniae isolate INV104. The polypeptides, including fragments and variants thereof, may be used in immunogenic compositions for prophylactic or therapeutic immunization against Streptococcus pneumoniae. The polypeptides are also disclosed to be used in compositions useful for the production of antibodies and immunostimulants. Also presented are methods of inhibiting Streptococcus pneumoniae, methods of treating Streptococcus pneumoniae infection, methods of identifying inhibitors of Streptococcus pneumoniae and methods for diagnosing / detecting Streptococcus pneumoniae infection.

The invention belongs to the technical field of screening and application of probiotics, and particularly relates to a Lactobacillus paracasei strain for preventing streptococcus infection of infants and an application of the Lactobacillus paracasei strain. The lactobacillus paracasei has a very strong antibacterial effect on beta-hemolytic streptococcus and is preserved in the China Center for Type Culture Collection on May 24, 2021, and the preservation number of the lactobacillus paracasei is CCTCC (China Center for Type Culture Collection) NO: M2021591. The strain can effectively prevent streptococcus infection, especially streptococcus infection of infants, can significantly reduce the level of inflammatory factors in the body, alleviate the degree of shedding of intestinal mucosa layers, keep the mesenteric structure complete, and alleviate inflammatory cell infiltration and splenomegaly, and has outstanding effects. The lactobacillus paracasei can be used for preparing food, health care products, medicines or skin care products with the function of preventing streptococcus infection, and the application prospect is wide.

Provide is a novel prophylactic and / or therapeutic agent for Streptococcus pneumoniae infection. It was found that a bacterium belonging to the genus Enterococcus can prevent and / or treat Streptococcus pneumoniae infection. The prophylactic and / or therapeutic agent for Streptococcus pneumoniae infection, comprises a bacterium belonging to the genus Enterococcus. Also provided are: a medicine for prevention and / or treatment of Streptococcus pneumoniae infection, comprising a bacterium belonging to the genus Enterococcus; and a food for prevention and / or treatment of Streptococcus pneumoniae infection, comprising a bacterium belonging to the genus Enterococcus.

Belonging to the technical field of veterinary microbiology and animal immunology, the invention discloses cloning of Streptococcus suis type 2 cell wall protein gene main functional domain fragment and application of the recombinant protein expressed by the fragment in Streptococcus suis type 2 antibody detection. The invention prepares an expression strain Escherichia coli BL21 / pET28a-sspA able to secrete Streptococcus suis type 2 cell wall protein SspA, and the preservation number is CCTCC NO: M2014344. The invention also discloses establishment of an SspA recombinant protein based ELISA detection method and application in detection of Streptococcus suis type 2 antibodies. A large number of SSPA antibodies exist in swine infected serum, and the antibody of the protein cannot be detected in immune serum. The method provided by the invention can be employed to detect swine serum antibody and can distinguish Streptococcus suis type 2 infection and immune animals.

The invention belongs to the technical field of prevention and treatment of animal infectious diseases, and particularly relates to application of a PBD-2 (Porcine Beta-Defensin 2) peptide fragment topreparation of a medicine composition for preventing and treating streptococcus suis infection. The PBD-2 peptide fragment has no cytotoxicity in vitro and has an obvious inhibition effect on streptococcus suis growth. Through PBD-2 treatment, the mortality rate, the inflammatory cytokine level, the tissue bacterial load quantity and the pathology damage degree of mice infected with streptococcussuis can be obviously reduced. The invention provides basic candidate medicine for pharmaceutical application of the PBD-2 peptide fragment to preparation of medicine for preventing and treatment thestreptococcus suis infection.

The present invention relates to an immunogenic complex comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, and a capsular polysaccharide. The immunogenic complex is capable of eliciting protective immunity against group B Streptococcus. The invention further pertains to an immunogenic product comprising the immunogenic complex and an immunogenic fusion protein, the vaccine, the immunogenic complex, or the immunogenic product for use in a method of preventing or treating a group B Streptococcus infection, as well as a method of preventing or treating a group B Streptococcus infection.

The invention discloses a care solution for cleaning a nasal cavity and a preparation method of the care solution. The care solution is prepared from 5,000 parts of traditional Chinese medicine distillate, 0.1-2 parts of preservatives, 1-100 parts of glyceryl polymethacrylate, 20-100 parts of tween 80, 30-80 parts of sodium chloride, 20-60 parts of a pH conditioning agent and 4658-4928.9 parts of purified water. The osmotic pressure of the care solution is 280-310mosm / Kg, and the pH value is 5.5-7.0. The preparation method of the care solution mainly comprises the following steps: by taking one or combination of houttuynia cordata, mint, honeysuckle and radix angelicae as raw materials, carrying out steam distillation to obtain the traditional Chinese medicine distillate; matching with auxiliary materials, and then filtering and carrying out split charging, so as to obtain the care solution. The solution disclosed by the invention has a strong inhibiting effect on nasal common microbe streptococcus infection, staphylococcus, bacillus influenza, influenza viruses and rhinoviruses, and can achieve the target of preventing rhinitis infection and recurrence.

The invention discloses a method for detecting group B streptococcus infections and belongs to methods for determining characteristics of in-vivo blood. According to the method, a kit contains reagents for detection, such as a negative control serum, a positive control serum, a concentrated phosphate buffer, an adsorbent, isosulfocyanic acid fluorescein-labeled sheep anti-human-IgM globulin and a mounting medium and a biological thin sheet, and reaction areas of the biological thin sheet are coated with group B streptococci. A determination method comprises the steps of adding an IgG antibody removed diluted serum into the reaction areas, carrying out incubation, rinsing and spin-drying, then, adding the isosulfocyanic acid fluorescein-labeled sheep anti-human-IgM globulin, forming isosulfocyanic acid fluorescein-labeled sheep anti-human-IgM globulin fluorescent complexes around thalli, and generating green-yellow fluorescence. According to the method disclosed by the invention, indexes such as sensitivity and specificity are all higher than that of the existing methods.

Isolated proteins and immunogenic fragments thereof, for use in the treatment and prevention of a Group A Streptococcus infection are provided. In particular, the invention provides pharmaceutical compositions and methods of prophylactic and / or therapeutic treatment of a Group A Streptococcus infection.

The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.

The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.

The present invention relates to an immunogenic complex comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, and a capsular polysaccharide. The immunogenic complex is capable of eliciting protective immunity against group B Streptococcus. The invention further pertains to an immunogenic product comprising the immunogenic complex and an immunogenic fusion protein, the vaccine, the immunogenic complex, or the immunogenic product for use in a method of preventing or treating a group B Streptococcus infection, as well as a method of preventing or treating a group B Streptococcus infection.

The recombinant production of Gap4, a chimeric GapC plasmin binding protein comprising the entire amino acid sequence of the Streptococcus dysgalactiae GapC protein in addition to unique amino acid sequences from the Streptococcus parauberis and Streptococcus agalactiae GapC proteins, is described. Also described is the use of Gap4 chimeric GapC protein in vaccine compositions to prevent or treat streptococcal infections in general and mastitis in particular.

The invention discloses streptococcus and a dairy cow mastitis vaccine obtained by inactivating the streptococcus. The active components of the dairy cow mastitis vaccine are an inactivated strain SAWR-6 (streptococcus agalactiae-6), an inactivated strain SDTR-9 (streptococcus dysgalactiae-9) and an inactivated strain SURF-5 (streptococcus uberis-5). The invention also provides a dairy cow mastitis vaccine, of which the active components are inactivated strains and capsular polysaccharides, wherein the inactivated strains are an inactivated strain SAWR-6, an inactivated strain SDTR-9 and an inactivated strain SURF-5; the capsular polysaccharides are strain SAWR-6 capsular polysaccharide, strain SDTR-9 capsular polysaccharide and strain SURF-5 capsular polysaccharide. The vaccine disclosed by the invention has the advantages of high efficiency, universality, safety, stability, various preparations and the like, a powerful guarantee is provided to safe, effective and comprehensive and effective prevention of streptococcus infected dairy cow mastitis, and the vaccine is a new milestone for the development of dairy cow mastitis vaccine.

The invention belongs to the technical field of screening and application of probiotics, and particularly relates to a novel lactobacillus paracasei strain and an application of the lactobacillus paracasei strain. The provided lactobacillus paracasei is separated from fresh excrement of healthy infants, and is preserved in the China Center for Type Culture Collection on May 24, 2021, and the preservation number of the lactobacillus paracasei is CCTCC (China Center for Type Culture Collection) NO: M2021590. The strain has a very strong antibacterial effect on beta-hemolytic streptococcus, can improve the immunity of a host, relieve inflammatory response and effectively prevent and treat infection caused by streptococcus, and is particularly suitable for preventing streptococcus infection of infants.

The invention discloses the application of SPD_0310 protein as a target in the preparation of medicines for preventing and treating Streptococcus pneumoniae infection. In the present invention, it was found that the expression level of SPD_0310 in the triple mutant strain in which the three main iron transport genes of Streptococcus pneumoniae were knocked out at the same time was increased and could grow normally, indicating that the SPD_0310 protein may be involved in the interaction of various iron transport proteins. The present invention also found that the spd_0310 gene knockout strain has reduced infectivity to mice. Based on this, SPD_0310 can be used to prepare antibodies to the protein, so as to facilitate the development of antibody drugs. In addition, the present invention also found that the active center of the protein can bind heme, and proved that porphyrins can be used as substrates to compete with heme, indicating that porphyrins can be used as inhibitors of SPD_0310 to inhibit Streptococcus pneumoniae toxicity, which has broad application prospects in the field of antibacterial drugs.